ZLAB - Zai Lab Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
36.33
+0.74 (+2.08%)
At close: 4:00PM EDT

36.33 0.00 (0.00%)
After hours: 4:27PM EDT

Stock chart is not supported by your current browser
Previous Close35.59
Open35.79
Bid35.77 x 800
Ask36.39 x 1400
Day's Range35.68 - 36.56
52 Week Range14.29 - 36.78
Volume154,245
Avg. Volume231,912
Market Cap2.12B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.64
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.84
Trade prices are not sourced from all markets
  • Here is What Hedge Funds Think About Zai Lab Limited (ZLAB)
    Insider Monkey18 days ago

    Here is What Hedge Funds Think About Zai Lab Limited (ZLAB)

    Insider Monkey has processed numerous 13F filings of hedge funds and successful investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find write-ups about an individual hedge fund's trades on numerous financial news […]

  • MarketWatch21 days ago

    Incyte enters license pact with Zai Lab to commercialize its cancer treatment in Greater China

    Incyte Corp. said Tuesday it will receive an upfront payment of $17.5 million as part of a license agreement with Zai Lab Ltd. for the development and commercialization of Incyte's cancer treatment INCMGA0012 in China. Under terms of the agreement, Incyte is eligible to receive up to an additional $60 million in milestone payments, as well as tiered royalty payments from the "low to mid-twenties." In return, Zai Lab will have exclusive rights to commercialize INCMGA0012 in China, Hong Kong, Macau and Taiwan. Incyte and Zai Lab shares were still inactive in the premarket. Over the past three months, Incyte shares have lost 1.5% and Zai Lab's stock has climbed 19.4%, while the iShares Nasdaq Biotechnology ETF has slipped 2.7% and the S&P 500 has gained 3.4%.

  • Business Wire21 days ago

    Incyte and Zai Lab Announce Collaboration and License Agreement for INCMGA0012 in Greater China

    Incyte (INCY) and Zai Lab Ltd. (ZLAB) today announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. Under the terms of the agreement, Zai Lab will pay Incyte US$17.5 million up front, and Incyte is eligible to receive up to an additional US$60 million in potential development, regulatory and commercial milestones, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics, Inc. Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan.

  • GlobeNewswirelast month

    Zai Lab Announces Approval to Commercialize ZEJULA (Niraparib) in Macau for Patients with Relapsed Ovarian Cancer

    SHANGHAI, China and SAN FRANCISCO, June 12, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, today announced its.

  • Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)?
    Simply Wall St.last month

    Do Insiders Own Lots Of Shares In Zai Lab Limited (NASDAQ:ZLAB)?

    If you want to know who really controls Zai Lab Limited (NASDAQ:ZLAB), then you'll have to look at the makeup of its...

  • GlobeNewswirelast month

    Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China

    Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, and Zai Lab Ltd. (ZLAB), a China and U.S.-based innovative biopharmaceutical company, today announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China (mainland China, Hong Kong, Macau and Taiwan). Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRα.

  • GlobeNewswire2 months ago

    Zai Lab Appoints Valeria Fantin, Ph.D., as Chief Scientific Officer

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Valeria Fantin, Ph.D. as Chief Scientific Officer. Dr. Fantin will lead the Company’s internal drug discovery effort on a global basis and will be based in the Company’s U.S. Headquarters in San Francisco, reporting to Dr. Samantha Du.  Dr. Fantin joins Zai Lab from ORIC Pharmaceuticals, where she served as Chief Scientific Officer. “Valeria is an accomplished research leader and brings more than 20 years of oncology drug discovery expertise and research experience to Zai Lab,” said Dr. Samantha Du, Zai Lab’s Founder and Chief Executive Officer.

  • GlobeNewswire2 months ago

    Zai Lab Announces Presentations at June Conferences

    SHANGHAI, China, May 29, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswire2 months ago

    Zai Lab Announces CTA Approval to Initiate a Phase 3 Clinical Trial of ETX2514SUL for the Treatment of Carbapenem-Resistant Acinetobacter Infections

    Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the Company’s Clinical Trial Application (CTA) to allow for the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of ETX2514SUL, a fixed-dosed combination of a broad spectrum β-lactamase inhibitor with sulbactam, for the treatment of patients with pneumonia and blood stream infections caused by carbapenem-resistant A. baumannii. “Carbapenem-resistant A. baumannii infections are a very serious public health problem in China because options to treat them are quite limited leading to a high mortality rate,” said Harald Reinhart, M.D., Chief Medical Officer of Zai Lab.

  • GlobeNewswire2 months ago

    Zai Lab Announces Participation at Upcoming May Conferences

    SHANGHAI, China, May 09, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)
    Insider Monkey3 months ago

    Here’s What Hedge Funds Think About Zai Lab Limited (ZLAB)

    Is Zai Lab Limited (NASDAQ:ZLAB) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]

  • GlobeNewswire3 months ago

    Zai Lab Announces Pricing of Public Offering of American Depositary Shares

    SHANGHAI, China, May 02, 2019 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company,.

  • 3 Top Chinese Stocks to Watch in May
    Motley Fool3 months ago

    3 Top Chinese Stocks to Watch in May

    If you're looking for high-growth opportunities, China has plenty.

  • GlobeNewswire3 months ago

    Zai Lab Announces Proposed Public Offering of American Depositary Shares

    SHANGHAI, China, May 01, 2019 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.

  • GlobeNewswire3 months ago

    Zai Lab to Host Analyst & Investor Day on April 30, 2019

    SHANGHAI, China, April 17, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%?
    Simply Wall St.4 months ago

    Did Zai Lab's (NASDAQ:ZLAB) Share Price Deserve to Gain 38%?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boo...

  • GlobeNewswire4 months ago

    Zai Lab Announces Presentations at March Conferences

    SHANGHAI, China, March 12, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that members of.

  • GlobeNewswire5 months ago

    Zai Lab Announces Financial Results and Corporate Update for Full Year 2018

    -- Zai Lab to Host Conference Call and Webcast Today at 8:30 a.m. EST-- SHANGHAI, China, March 07, 2019 -- Zai Lab Limited (“Zai lab” or the Company) (NASDAQ: ZLAB), a China.

  • Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript

    MGNX earnings call for the period ending December 31, 2018.

  • GlobeNewswire5 months ago

    Zai Lab to Announce Full Year 2018 Financial Results

    SHANGHAI, China, Feb. 21, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, today announced that it will.

  • GlobeNewswire5 months ago

    Zai Lab to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    SHANGHAI, China, Feb. 20, 2019 -- Zai Lab Limited (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that Tao Fu,.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 6) Array Biopharma Inc (NASDAQ: ARRY ) Millendo Therapeutics ...